Epizyme Inc (NASDAQ:EPZM) – Investment analysts at Svb Leerink issued their FY2024 earnings estimates for shares of Epizyme in a research note issued to investors on Friday, January 24th. Svb Leerink analyst A. Berens anticipates that the biopharmaceutical company will earn ($0.03) per share for the year. Svb Leerink currently has a “Market Perform” rating on the stock.
Other equities analysts also recently issued reports about the company. Leerink Swann downgraded Epizyme from an “outperform” rating to a “market perform” rating and set a $18.00 target price on the stock. in a research report on Friday. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating and set a $11.00 target price on the stock. in a research report on Monday, October 21st. BidaskClub upgraded Epizyme from a “hold” rating to a “buy” rating in a research report on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, Cowen increased their target price on Epizyme from $18.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $25.13.
NASDAQ EPZM opened at $21.36 on Monday. The business’s 50-day moving average price is $22.62 and its 200 day moving average price is $15.29. Epizyme has a twelve month low of $8.98 and a twelve month high of $27.82. The company has a market capitalization of $1.95 billion, a PE ratio of -13.27 and a beta of 2.68. The company has a current ratio of 10.90, a quick ratio of 10.90 and a debt-to-equity ratio of 0.03.
Epizyme (NASDAQ:EPZM) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.11. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. The firm had revenue of $5.72 million for the quarter, compared to the consensus estimate of $5.50 million.
Institutional investors have recently added to or reduced their stakes in the company. Vigilant Capital Management LLC purchased a new stake in shares of Epizyme during the 4th quarter valued at about $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Epizyme by 29.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 1,262 shares during the period. Perigon Wealth Management LLC purchased a new stake in shares of Epizyme during the 4th quarter valued at about $201,000. United Services Automobile Association purchased a new stake in shares of Epizyme during the 2nd quarter valued at about $134,000. Finally, Man Group plc purchased a new stake in shares of Epizyme during the 2nd quarter valued at about $222,000. Institutional investors own 87.04% of the company’s stock.
In other news, CEO Robert B. Bazemore sold 6,074 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $20.44, for a total value of $124,152.56. Following the transaction, the chief executive officer now directly owns 93,744 shares in the company, valued at approximately $1,916,127.36. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Shefali Agarwal sold 2,630 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $20.44, for a total value of $53,757.20. Following the completion of the transaction, the insider now owns 63,276 shares in the company, valued at $1,293,361.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,549 shares of company stock worth $297,231. Company insiders own 16.60% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company’s lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.